NGM Biopharmaceuticals Inc (NGM)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David J. Woodhouse
Employees:
333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA 94080
650-243-5555

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Data derived from most recent annual or quarterly report
Market Cap 1.477 Billion Shares Outstanding77.338 Million Avg 30-day Volume 332.443 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 32.12 / 14.9 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from NGM instead.

View recent insider trading info

Funds Holding NGM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NGM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

62 Thousand total shares from 8 transactions

Exercise Derivative Conversion (M)

2 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CHEN JIN-LONG CHIEF SCIENTIFIC OFFICER

  • Officer
  • Director
899,449 2021-10-11 12

LIEU HSIAO D SVP, CHIEF MEDICAL OFFICER

  • Officer
190,000 2021-10-05 3

LESCHLY MARK

  • Director
19,619 2021-06-08 1

GOEDDEL DAVID V

  • Director
  • 10% Owner
19,619 2021-06-08 1

PERLMUTTER ROGER M

  • Director
46,238 2021-06-08 2

HOOPER SUZANNE SAWOCHKA

  • Director
19,619 2021-06-08 1

GUYER SHELLY D

  • Director
19,619 2021-06-08 1

HO CAROLE

  • Director
19,619 2021-06-08 1

RIEFLIN WILLIAM JL EXECUTIVE CHAIRMAN

  • Officer
  • Director
80,000 2021-03-17 1

PIERCE VALERIE L SVP, GC & CCO

  • Officer
100,000 2021-03-17 2

WOODHOUSE DAVID J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
450,000 2021-03-17 1

NOLAN MANGINI SIOBHAN CHIEF FINANCIAL OFFICER

  • Officer
50,000 2021-03-17 1

COLUMN GROUP L P

COLUMN GROUP III, LP

COLUMN GROUP III-A, LP

COLUMN GROUP III GP, LP

SVENNILSON PETER

GOEDDEL DAVID V

  • Director
  • 10% Owner
  • GENERAL PARTNERMANAGING PARTNERMANAGING PARTNER
18,242,932 2020-09-01 0

COLUMN GROUP L P

COLUMN GROUP GP, LP

COLUMN GROUP II, LP

COLUMN GROUP II GP, LP

COLUMN GROUP MANAGEMENT LP

PONOI CAPITAL, LP

PONOI MANAGEMENT, LLC

PONOI CAPITAL II, LP

PONOI II MANAGEMENT, LLC

KUTZKEY TIM

  • Director
  • 10% Owner
  • GENERAL PARTNER GENERAL PARTNER GENERAL PARTNERMANAGING PARTNER
18,242,932 2020-09-01 0

TICHENOR MCHENRY T

  • Director
0 2020-05-20 0

SCHNELL DAVID

  • Director
0 2020-05-20 0

COLUMN GROUP L P

COLUMN GROUP III, LP

COLUMN GROUP III-A, LP

COLUMN GROUP III GP, LP

  • 10% Owner
  • GENERAL PARTNER
17,721,978 2020-04-08 0

SVENNILSON PETER

  • Director
  • 10% Owner
17,726,978 2020-04-08 0

TROMBLEY AETNA WUN PRESIDENT & COO

  • Officer
0 2020-02-04 0

COLUMN GROUP III, LP

COLUMN GROUP III-A, LP

COLUMN GROUP III GP, LP

  • 10% Owner
  • GENERAL PARTNER
53,172 2019-10-09 0

COLUMN GROUP L P

PONOI CAPITAL II, LP

PONOI II MANAGEMENT, LLC

SVENNILSON PETER

KUTZKEY TIM

GOEDDEL DAVID V

  • Director
  • 10% Owner
  • GENERAL PARTNERMANAGING PARTNERMANAGING PARTNERMANAGING PARTNER
17,912,171 2019-05-15 0

COLUMN GROUP L P

COLUMN GROUP II, LP

COLUMN GROUP GP, LP

COLUMN GROUP II GP, LP

COLUMN GROUP MANAGEMENT LP

COLUMN GROUP III, LP

COLUMN GROUP III-A, LP

COLUMN GROUP III GP, LP

PONOI MANAGEMENT, LLC

PONOI CAPITAL, LP

  • Director
  • 10% Owner
  • GENERAL PARTNER GENERAL PARTNERGENERAL PARTNER
17,912,171 2019-05-15 0

MERCK & CO., INC.

MERCK SHARP & DOHME CORP.

  • 10% Owner
12,955,016 2019-04-08 0

PONOI CAPITAL, LP

PONOI MANAGEMENT, LLC

PONOI CAPITAL II, LP

PONOI II MANAGEMENT, LLC

KUTZKEY TIM

  • 10% Owner
  • GENERAL PARTNER GENERAL PARTNERMANAGING PARTNER
1,890,000 2019-04-08 0

COLUMN GROUP L P

COLUMN GROUP II, LP

COLUMN GROUP GP, LP

COLUMN GROUP MANAGEMENT LP

COLUMN GROUP II GP, LP

  • 10% Owner
  • GENERAL PARTNER GENERAL PARTNER
475,957 2019-04-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CHEN JIN-LONG - Director - Officer CHIEF SCIENTIFIC OFFICER

2021-10-13 16:34:52 -0400 2021-10-12 S 15,000 $20.14 d 899,449 direct yes -2.8628 -4.9852 0.0 1 -5.6269 3

CHEN JIN-LONG - Director - Officer CHIEF SCIENTIFIC OFFICER

2021-10-13 16:34:52 -0400 2021-10-11 S 15,000 $20.41 d 914,449 direct yes -2.8628 -4.9852 0.0 1 -5.6269 3

LIEU HSIAO D - Officer SVP, CHIEF MEDICAL OFFICER

2021-10-07 20:04:44 -0400 2021-10-05 M 2,000 $12.06 a 2,000 direct yes 1.332 -2.9107 1.332 2 -2.9107 6

LIEU HSIAO D - Officer SVP, CHIEF MEDICAL OFFICER

2021-10-07 20:04:44 -0400 2021-10-05 M 2,000 d 190,000 direct yes

LIEU HSIAO D - Officer SVP, CHIEF MEDICAL OFFICER

2021-10-07 20:04:44 -0400 2021-10-05 S 2,000 $22.00 d 0 direct yes 1.332 -2.9107 1.332 2 -2.9107 6

CHEN JIN-LONG - Director - Officer CHIEF SCIENTIFIC OFFICER

2021-09-14 21:27:48 -0400 2021-09-14 S 3,037 $26.13 d 929,449 direct yes -7.0203 -12.5975 0.0 1 -13.1435 4

CHEN JIN-LONG - Director - Officer CHIEF SCIENTIFIC OFFICER

2021-09-14 21:27:48 -0400 2021-09-14 S 11,963 $25.54 d 932,486 direct yes -7.0203 -12.5975 0.0 1 -13.1435 4

CHEN JIN-LONG - Director - Officer CHIEF SCIENTIFIC OFFICER

2021-09-14 21:27:48 -0400 2021-09-13 S 3,920 $25.59 d 955,529 direct yes -7.0203 -12.5975 0.0 1 -13.1435 4

CHEN JIN-LONG - Director - Officer CHIEF SCIENTIFIC OFFICER

2021-09-14 21:27:48 -0400 2021-09-13 S 170 $26.98 d 944,449 direct yes -7.0203 -12.5975 0.0 1 -13.1435 4

CHEN JIN-LONG - Director - Officer CHIEF SCIENTIFIC OFFICER

2021-09-14 21:27:48 -0400 2021-09-13 S 10,910 $26.17 d 944,619 direct yes -7.0203 -12.5975 0.0 1 -13.1435 4

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 22:15:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 21:45:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 21:15:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 20:45:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 20:15:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 19:45:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 19:15:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 18:45:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 18:15:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 17:45:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 17:15:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 16:45:04 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 16:15:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 15:45:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 15:15:03 UTC -0.18 0.25 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 14:45:03 UTC -0.3255 0.3955 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 14:15:05 UTC -0.3255 0.3955 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 13:45:03 UTC -0.3255 0.3955 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 13:15:03 UTC -0.3255 0.3955 300000
NGM BIOPHARMACEUTICALS INC NGM 2021-10-26 12:45:03 UTC -0.3255 0.3955 300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund NGM -32.0 shares, $-394.56 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund NGM -20.0 shares, $-246.6 2020-03-31 N-PORT

Elevate your investments